Alternating hemiplegia of childhood …

Nina F. Schor MD PhD

Headache & Pain

Updated 10.11.2023
Released 07.01.1993
Expires For CME 10.11.2026

Alternating hemiplegia of childhood

Author: Nina F. Schor MD PhD

See Contributor Disclosures

Editor: Stephen D Silberstein MD

Alternating hemiplegia of childhood

In This Article

Quick Link

Introduction

Overview

Alternating hemiplegia of childhood is a rare disorder caused by mutations in the ATP1A3 gene, a gene that encodes the alpha3 subunit of Na,K-ATPase, thought to be neuron-specific. It is manifested by episodes of unusual posturing, hemiplegia, and progressive developmental and behavioral disturbance and seizures. At its onset in early childhood, the differential diagnosis is broad and includes more common childhood disorders, such as epilepsy. Flunarizine may decrease the frequency of spells and possibly moderate the disorder, but is not available in the United States. Reports suggest that ketogenic diet therapy is helpful as well. Other phenotypes, including rapid-onset dystonia-parkinsonism (RDP) cerebellar ataxia, areflexia, pes cavus, optic atrophy, sensorineural deafness (CAPOS), and hemidystonia with polymicrogyria have been associated with mutations in the same gene.

Key points

	• Alternating hemiplegia of childhood is a rare disorder that, at onset, may mimic other neurologic disorders in children and requires a thorough evaluation to exclude other causes.
	• Both familial and sporadic cases are associated with causative mutations in the ATP1A3 gene.
	• Flunarizine, available in Europe, and ketogenic diet therapy have been reported to be helpful in this disorder.

Historical note and terminology

Alternating hemiplegia is a rare disorder of childhood originally described by Verret and Steele as a form of hemiplegic migraine of infancy (43). Subsequent reports suggested that the syndrome was a variant of complicated or basilar migraine despite important differences in symptoms and course. Krageloh and Aicardi were the first to emphasize that alternating hemiplegia of childhood is a nosologic entity distinct from migraine (11). The International Classification of Headache Disorders (06) lists alternating hemiplegia of childhood as a syndrome that may be associated with migraine. However, the association is not clear, and familial hemiplegic migraine type 2 is associated with mutations in a gene (ATP1A2) that codes for a different subunit of the Na,K-ATPase protein. Others have subsequently underscored the uniqueness of alternating hemiplegia as a clinical entity (23; 22). Revision of the diagnostic criteria for alternating hemiplegia of childhood has been proposed (17).

Clinical manifestations

Presentation and course

The classical clinical features of this disorder are as follows (01):

	(1) Onset before 18 months of age;
	(2) Recurrent attacks of hemiplegia involving either side of the body;
	(3) Other paroxysmal episodes, including tonic spells, dystonia, chorea, nystagmus, dyspnea, and autonomic disturbances, occurring in association with the episodes of hemiplegia or independently;
	(4) Episodes of bilateral hemiplegia either at the onset of the attack or as the attack shifts from one side of the body to the other;
	(5) Resolution of the hemiplegia with the onset of sleep and prolonged episodes of recurrence 10 to 20 minutes after awakening;
	(6) Evidence of developmental delay and other neurologic abnormalities such as choreoathetosis, dystonia, and ataxia.

The presence of all of these criteria is not necessary to make the diagnosis in an otherwise typical case. Eighty-five percent of patients have paroxysmal eye movements within the first 3 months of life, which often herald the onset of symptoms. Thirty-two percent of patients had abnormal eye movements, often nystagmus, noted within 1 to 2 days of birth (37; 30). The patient may have episodes of head and eye deviation with ipsilateral limb extension associated with crying. Nystagmus and dyspnea may also occur. Hemiplegia of the affected side may follow. Consciousness is preserved. The duration of these attacks may vary from minutes to days. Hemiplegia is aborted with sleep but may recur on awakening. Episodes of quadriparesis may occur. The patients are usually flaccid unless there is superimposed dystonia. Episodes of dystonia, nystagmus, dyspnea, and autonomic symptoms, such as flushing or pallor, may occur independently of hemiplegic episodes. Some children may develop normally initially; however, developmental delay is usual. Chronic ataxia and choreoathetotic movements may develop during the course of the disorder and remain (22; 44).

According to a published series of 44 patients (16), the course of the disorder appears to consist of 3 phases. The first phase, lasting about 1 year, is characterized by mild developmental delay, intermittent nystagmus or eye deviation, and dystonic episodes. During the second phase, evolving over 1 to 5 years, patients experience episodes of hemiplegia and quadriplegia, lose developmental milestones, and begin to exhibit fixed neurologic deficits, choreoathetosis, and ataxia. During the third phase, patients continue to have episodes of hemiplegia, although at a lesser frequency, and neurologic deterioration plateaus. Earlier onset of the disorder appears to portend a poorer neurologic prognosis. A few patients, typically those with later onset or fewer spells, may maintain normal or near-normal intellect.

A study of 187 patients in the United States AHCF Registry (45) demonstrated a mean age of onset of paroxysmal symptoms of between 1.9 and 12.2 months of age, depending on the causative mutation involved. Between 50% and 80% of patients develop epilepsy, and most have developmental delay and cognitive impairment of variable severity, and genotype-phenotype correlations are relevant to these manifestations as well, although they are not reliable enough to provide prognostic information for the individual patient or family (18; 45).

In view of the genotypic and phenotypic heterogeneity of children with alternating hemiplegia of childhood, Mikati and colleagues have proposed assigning the diagnosis to children who manifest both of the essential criteria, plus either 3 major or 2 major and 3 minor criteria, as defined below (17):

	(1) Essential criteria
		(a) Paroxysmal episodes of hemiplegia that alternate between the 2 sides and/or of quadriplegia
		(b) Evidence of abnormal baseline neurologic development
	(2) Major criteria
		(a) Onset before 18 months of age
		(b) Episodes of dystonia
		(c) Different types of episodes occur independently or together at the same time with evolution from 1 or more symptoms to others during that 1 episode
		(d) Paroxysmal episodes of abnormal eye movements such as nystagmus and especially monocular nystagmus
		(e) ATP1A3 mutation
		(f) Plegic spells improve with sleep
	(3) Minor criteria
		(a) Epileptic spells alone or in combination with nonepileptic spells
		(b) Nonepileptic episodes of altered consciousness alone or in combination with other spells
		(c) Abnormal tone and/or motor function, often including coexistent hypotonia and dystonia, ataxia, choreoathetosis, and poor oral motor control
		(d) Episodes of autonomic dysfunction

Diagnostic workup at onset, including brain imaging, routine EEG, serum amino acid studies, urine organic acid assays, mitochondrial studies, and muscle biopsy, is normal. Ictal EEG can be normal as well (37).

Prognosis and complications

In typical cases of alternating hemiplegia of childhood with early childhood onset, motor and cognitive disability occurs. Many patients with this disorder develop intellectual impairment, spasticity, seizures, ataxia, and choreoathetosis. Developmental delay is a variable feature at onset. In a series of 9 patients, seizures typically developed after 2 years of age (31). The occurrence of status epilepticus correlated with poorer neurologic outcome. Patients in this group frequently show cerebellar atrophy and high signal in the hippocampus on MRI over time. However, 1 comprehensive longitudinal study of 157 patients with a mean onset of symptoms of 3.5 months showed no progression of clinical manifestations over up to 52 years. Most of the data for this study were collected retrospectively, but all patients were followed prospectively for 2 years. In addition, in this study, no statistically significant correlation between a history of severe paroxysmal hemiplegic/dystonic episodes and a worse neurologic outcome was identified (20). A longitudinal study underscores the progressive potential of this disorder in some patients (26).

Premature mortality has been described in patients with alternating hemiplegia of childhood and is unexplained by seizures or neurologic dysfunction alone. A study of 52 DNA-confirmed cases of alternating hemiplegia of childhood and 52 disease controls with epilepsy suggested that electrocardiographic abnormalities are more common in patients with alternating hemiplegia than in control patients with epilepsy, and have characteristics reflecting those of inherited cardiac channelopathies and most likely relate to impaired repolarization reserve (08).

Clinical vignette

A family was described by Rodriguez-Quiroga and colleagues and the vignette below is derived from this description (29).

A 19-year-old man first came to medical attention with anarthria, mild dysphagia, hypotonia, and severe bradykinesia involving all 4 limbs, and affecting face greater than arms and greater than legs. Tremor and stooped posture, frequently seen in Parkinson disease, were notably absent. Twelve other family members were interviewed and examined and the family was found to include individuals with episodic hemiplegia, epilepsy, mild cognitive impairment, developmental delay, dystonia, parkinsonism, and/or bulbar dysfunction. The pedigree of all neurologic dysfunction in this family was consistent with an autosomal dominant inheritance pattern. The affected family members were found to have a novel missense mutation in the gene ATP1A3.

Biological basis

Etiology and pathogenesis

Alternating hemiplegia is caused by mutations in the ATP1A3 gene. This gene codes for the alpha3 subunit of the Na,K-ATPase, a protein that is neuron-specific and highly expressed in the basal ganglia, cortex, hippocampus, and thalamus (13). Two mutations, D801N and E815K, predominate and a more severe phenotype generally is seen in the E815K cohort. For example, patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment, and a higher prevalence of status epilepticus. Of 34 unique mutations found by Viollet and colleagues in a study of 187 subjects, 31 (91%) were missense. Most of these mutations are clustered in exons 17 and 18 (45).

In a study of 155 patients meeting clinical criteria for alternating hemiplegia of childhood, Panagiotakaki and colleagues identified 132 patients with, collectively, 34 different mutations of ATP1A3 (19). In addition to finding differences in overall disease severity and age at onset of epilepsy, they found that mutations clustered in 5 distinct regions of the ATP1A3 gene, and there was some correlation between the region in which the mutation occurred and disease phenotype.

Development of a Xenopus oocyte model of mutant alpha3 expression has given rise to the functional correlate of this mutation with aberrant forward cycling in neurons. Forward cycling refers to the process by which ATP hydrolysis is used to drive the exchange of 3 Na+ outward for 2 K+ inward at the cell membrane. Under some conditions, this protein also serves as an ATP-driven H+ pump. In the oocyte model, the D801N, G947R, and E815K mutants of the alpha3 subunit are dominant negative and result in loss of forward cycling and consequent proton pumping by the Na+,K+ ATPase. It is not yet known how loss of forward cycling contributes to the clinical findings in alternating hemiplegia of childhood (13).

A murine knock-in model of mutant ATP1A3 expression demonstrates abnormal impulsivity, memory, gait, motor coordination, tremor, motor control, endogenous nociceptive response, paroxysmal hemiplegias, diplegias, dystonias, spontaneous recurrent seizures, and predisposition to sudden unexpected death. Electrophysiologically, hippocampal slices from these animals demonstrate hyperexcitable responses to 1 Hz pulse-trains of electrical stimuli delivered to the Schaffer collaterals and significantly longer duration of K+-induced spreading depression responses than controls (07).

Clinically, there is an expanding array of phenotypes associated with mutations in ATP1A3, suggesting that the specific mutation involved and/or epigenetic factors may modulate the manifestations of the genetic abnormality in a given patient and family (02; 32). One study of 39 Italian patients divided the cohort into 3 groups according to genotype and found evidence for correlation between genotype and phenotype in the disorder (03). In this cohort, 92.3% of the patients had a mutation of ATP1A3. Those with a p.Glu815Lys mutation constituted 23% of the sample and demonstrated earlier onset of plegic episode, were more frequently hypotonic and nonambulatory, more frequently had epilepsy, and had more severe dystonia than those with an p.Asp801Asn mutation (26% of the sample). The remaining patients with mutations of ATP1A3 had a variety of other mutations with generally later onset of symptoms and less severe disease. Patients with a p.Glu815Lys mutation were the most responsive to flunarizine in this study (03). A child with hemidystonia and polymicrogyria has been shown to have a de novo single nucleotide missense mutation (12).

A meta-analysis of studies collectively including 902 patients with ATP1A3 mutations demonstrated no consistent phenotype-genotype correlations; however, some interesting trends emerged. Complex rearrangements were found only in alternating hemiplegia of childhood. More than half of subjects with alternating hemiplegia of childhood had p.D801N or p.E815K mutation of ATP1A3; these mutations were not seen in any of the subjects with CAPOS. Patients who had both alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism tended not to have either of these two mutations either (14).

Differential diagnosis

Confusing conditions

Early in the course of the disorder, when dystonic rather than hemiplegic episodes are more common, the differential diagnosis is broad. Diagnostic considerations often include partial epilepsy, which may require routine EEG and prolonged EEG to differentiate. Idiopathic torsion dystonia, an inherited condition characterized by episodes of dystonia that may begin in early childhood, may mimic the early dystonic episodes of alternating hemiplegia of childhood. However, these children do not experience the developmental decline seen in alternating hemiplegia of childhood. Similarly, dopa-responsive dystonia, a disorder nearly identical in manifestation to idiopathic torsion dystonia, may also resemble alternating hemiplegia of childhood; however, these patients respond dramatically to levodopa. Children with paroxysmal dystonic choreoathetosis, an autosomal dominant disorder, may present in infancy with spells of dystonia lasting minutes to hours but remain neurologically normal. Children with paroxysmal kinesigenic choreoathetosis exhibit numerous, very brief episodes of dystonia or chorea that are provoked by movement. They also remain developmentally normal. In benign dystonia of infancy, dystonic episodes of an arm or leg occur; these are not associated with any other neurologic symptoms and resolve by 5 years of age. Secondary causes of dystonia in young children include glutaric aciduria, GM1 and GM2 gangliosidoses, Hartnup disease, pantothenate kinase-associated neurodegeneration (PKAN), mitochondrial cytopathy, and congenital and acquired lesions of the basal ganglia (41). A syndrome consisting of alternating hemiplegia and epilepsia partialis continua has been ascribed to mutations in the TBC1D24 gene (28). In addition, GLUT1 deficiency has occasionally been associated with paroxysmal hemiplegia and contralateral EEG slowing (25; 46). Children with mutations in ATP1A2 have also been reported to demonstrate alternating hemiplegia and familial hemiplegic migraine of childhood. One case report suggests that NMDA receptor antagonists can be helpful in this disorder and are thought to involve glutamatergic toxicity (40). Gene sequencing studies, imaging, metabolic studies, and clinical course can help to differentiate these disorders from alternating hemiplegia of childhood. For example, one study demonstrated that adding consideration of the Combined Annotation Dependent Depletion score, an algorithm-based mutation analysis tool that integrates consideration of many different aspects of mutation pathogenicity, can increase diagnostic certainty over consideration only of clinical phenotype (44).

When hemiplegic spells and cognitive deterioration become manifest, the differential may broaden to include stroke and moyamoya disease in addition to epilepsy and mitochondrial disease. Imaging (including MRI and MRA) may help to exclude these possibilities, although the increasing availability and decreasing cost of gene sequencing testing may make these unnecessary.

Associated or underlying disorders

Complications of anesthesia, whether for diagnostic procedures or surgery, are particularly prevalent in children with alternating hemiplegia. They include cardiac arrhythmias, hypotension, seizures, dystonic spells, and apnea (21). The possibility of a link between anesthetic complications and autonomic dysfunction in alternating hemiplegia has been raised (24).

Management

Although a curative treatment is not known, several medications appear to have some efficacy in preventing hemiplegic spells. Flunarizine, a calcium channel blocker used for migraine in Europe but not available in the United States, is felt to be the most effective agent for preventing hemiplegic spells and has also been purported to improve neurologic prognosis (16; 33; 27). No specific dosing guidelines have been established; however, doses ranging from 5 mg/kg every other day to 12 mg/kg per day have been used. No prospective studies have been published. Benzodiazepines and chloral hydrate have also been used as prophylactic agents, although it is not clear whether or not the response seen is secondary to the hypnotic effects of these agents (35; 42). Amantadine and memantine, noncompetitive NMDA receptor antagonists, have also been reported to reduce the frequency of hemiplegic spells in patients unresponsive to flunarizine (10; 36). Treatment with older anticonvulsants has not been found to be fruitful for episodes of hemiplegia, and even patients with epileptiform ictal EEGs are often drug-resistant (39); however, several case reports have reported efficacy of topiramate, an anticonvulsant and migraine prophylactic agent, both in patients who have failed flunarizine and as a first line agent (04; 09). Unfortunately, in the largest series published, only 1 of 16 patients treated with topiramate showed improvement (38). In a small observational study, 6 patients in whom a vagal nerve stimulator was implanted noted decreased seizure frequency and a modest, but not statistically significant decrease in dystonic episode (39). Another group reported reduction in the frequency, duration, and severity of hemiplegic episodes in a teenage patient with an established diagnosis of alternating hemiplegia of childhood and treated with aripiprazole, an antipsychotic. The patient was inadvertently given an inactive drug and had deterioration, with subsequent improvement on reinitiation of active drug. Several reports of improvement with ketogenic diet therapy suggest that this approach should be considered (34). In addition, a single case report suggests that aripiprazole may be of use in patients whose symptoms are refractory to flunarizine (05).

Optimal management of children with alternating hemiplegia of childhood is best accomplished with a multidisciplinary team-based approach (15).

References

01: Bourgeois M, Aicardi J, Goutieres F. Alternating hemiplegia of childhood. J Pediatr 1993;122:673-9. PMID 8496742
02: Carecchio M, Zorzi G, Ragona F, Zibordi F, Nardocci N. ATP1A3-related disorders: an update. Eur J Paediatr Neurol 2018;22(2):257-63. PMID 29291920
03: Cordani R, Stagnaro M, Piciotta L, et al. Alternating hemiplegia of childhood: Genotype-phenotype correlations in a cohort of 39 Italian patients. Front Neurol 2021;12:658451. PMID 33897609
04: Di Rosa G, Spano M, Pustorino G, et al. Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. Neurology 2006;66(1):146. PMID 16401872
05: Dundar NO, Cavusoglu D, Kaplan YC, Hasturk MO. An option to consider for alternating hemiplegia of childhood: aripiprazole. Clin Neuropharmacol 2019;42(3):88-90. PMID 30893129
06: Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Available at: https://ichd-3.org/. Accessed June 2019.
07: Hunanyan AS, Fainberg NA, Linabarger M, et al. Knock-in mouse model of alternating hemiplegia of childhood: behavioral and electrophysiologic characterization. Epilepsia 2015;56(1):82-93. PMID 25523819
08: Jaffer F, Avbersek A, Vavassori R, et al. Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. Brain 2015;138(Pt 10):2859-74. PMID 26297560
09: Jiang W, Chi Z, Ma L, et al. Topiramate: a new agent for patients with alternating hemiplegia of childhood. Neuropediatrics 2006;37(4):229-33. PMID 17177149
10: Korinthenberg R. Is infantile alternating hemiplegia mediated by glutamate toxicity and can it be treated with memantine. Neuropediatrics 1996;27(5):277-8. PMID 8971751
11: Krageloh I, Aicardi J. Alternating hemiplegia in infants: report of five cases. Dev Med Child Neurol 1980;22:784-91. PMID 7450304
12: Lacombe D, Van Gils J, Lebrun M, et al. Hemidystonia with polymicrogyria is part of ATP1A3-related disorders. Brain Devel 2022;44(2022):567-70. PMID 35623960
13: Li M, Jazayeri D, Corry B, et al. A functional correlate of severity in alternating hemiplegia of childhood. Neurobiol Dis 2015;77:88-93. PMID 25681536
14: Li Y, Liu X, Wang C, et al. Molecular and clinical characteristics of ATP1A3-related diseases. Front Neurol 2022;13:924788. PMID 35968298
15: Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and treatment of alternating hemiplegia of childhood. Curr Treat Options Neurol 2017;19(2):8. PMID 28337648
16: Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. Pediatr Neurol 2000;23:134-41. PMID 11020638
17: Mikati MA, Panagiotakaki E, Arzimanoglu A. Revision of the diagnostic criteria of alternating hemiplegia of childhood. Eur J Pediatr Neurol 2021;32:A4-5. PMID 33975787
18: Paciorkowski AR, McDaniel SS, Jansen LA, et al. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia 2015;56(3):422-30. PMID 25656163
19: Panagiotakaki E, De Grandis E, Stagnaro M, et al. Clinical profile of patients with ATP1A3 mutations in alternating hemiplegia of childhood – a study of 155 patients. Orphanet J Rare Dis 2015;10:123. PMID 26410222
20: Panagiotakaki E, Gobbi G, Neville B, et al. Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults. Brain 2010;133(Pt 12):3598-610. PMID 20974617
21: Parker LE, Wallace K, Thevathasan A, et al. Characterization of sedation and anesthesia complications in patients with alternating hemiplegia of childhood. Eur J Pediatr Neurol 2022;38(2022):47-52. PMID 35390560
22: Pavone P, Pappalardo XG, Mustafa N, et al. Alternating hemiplegia of childhood: neurological comorbidities and intrafamilial variability. Ital J Pediatr 2022b;48(1):29. PMID 35177115
23: Pavone P, Pappalardo XG, Ruggieri M, Falsaperla R, Parano E. Alternating hemiplegia of childhood: a distinct clinical entity and ATP1A3-related disorders: A narrative review. Medicine (Baltimore) 2022a;101(31):e29413. PMID 35945798
24: Pearl P. Autonomic risks in alternating hemiplegia of childhood. Eur J Pediatr Neurol 2022;38(2022):A3. PMID 35487825
25: Pellegrin S, Cantalupo G, Opri R, Dalla Bernardina B, Darra F. EEG findings during "paroxysmal hemiplegia" in a patient with GLUT1-deficiency. Eur J Paediatr Neurol 2017;21(3):580-2. PMID 28129950
26: Perulli M, Poole J, Di Lazzaro G, et al. Non-stationary outcome of alternating hemiplegia of childhood into adulthood. Movement Disord 2022;9(2):206-11. PMID 35141355
27: Pisciotta L, Gherzi M, Stagnaro M, et al. Alternating hemiplegia of childhood: pharmacological treatment of 30 Italian patients. Brain Dev 2017;39(6):521-8. PMID 28249736
28: Ragona F, Castellotti B, Salis B, et al. Alternating hemiplegia and epilepsia partialis continua: a new phenotype for a novel compound TBC1D24 mutation. Seizure 2017;47:71-3. PMID 28292732
29: Rodriguez-Quiroga SA, Gonzales-Moron D, Vishnopolska SA, et al. Expanding the spectrum of ATP1A3 related disorders: continuum from alternating hemiplegia of childhood to rapid-onset dystonia parkinsonism. Twentieth International Congress of Parkinson’s Disease and Movement Disorders, Abstract #592. Berlin, 2016.
30: Rosewich H, Sweney MT, DeBrosse S, et al. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. Neurol Genet 2017;3(2):e139. PMID 28293679
31: Saito Y, Inui T, Sakakibara T, Sugai K, Sakuma H, Sasaki M. Evolution of hemiplegic attacks and epileptic seizures in alternating hemiplegia of childhood. Epilepsy Res 2010;90(3):248-58. PMID 20580529
32: Salles PA, Mata IF, Brünger T, Lal D, Fernandez HH. ATP1A3-related disorders: an ever-expanding clinical spectrum. Front Neurol 2021;12:637890. PMID 33868146
33: Sasaki M, Sakuragawa N, Osawa M. Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan. Brain Dev 2001;23:303-5. PMID 11504600
34: Schirinzi T, Graziola F, Cusmai R, et al. ATP1A3-related epileptic encephalopathy responding to ketogenic diet. Brain Devel 2018;40(5):433-8. PMID 29395663
35: Siemes H, Cordes M. Single-photon emission computed tomography investigations of alternating hemiplegia of childhood. Dev Med Child Neurol 1993;35:346-50. PMID 8335150
36: Sone K, Oguni H, Katsumori H, Funatsuka M, Tanaka T, Osawa M. Successful trial of amantadine hydrochloride for two patients with alternating hemiplegia of childhood. Neuropediatrics 2000;31:307-9. PMID 11508550
37: Sweney MT, Newcome TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, alternating hemiplegia of childhood, rapid-onset dystonia-parkinsonism, CAPOS, and beyond. Ped Neurol 2015;52(1):56-64. PMID 25447930
38: Sweney MT, Silver K, Gerard-Blanluet M, et al. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. Pediatrics 2009;123(3):e534-41. PMID 19254988
39: Uchitel J, Helseth A, Prange L, et al. The epileptology of alternating hemiplegia of childhood. Neurology 2019;93(13):e1248-59. PMID 31484714
40: Ueda K, Serajee F, Huq AM. Clinical benefit of NMDA receptor antagonists in a patient with ATP1A2 gene mutation. Pediatrics 2018;141(Suppl 5):S390-4. PMID 9039526
41: van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry 2015;86(7):774-81. PMID 25395479
42: Veneselli E, Biancheri R. Alternating hemiplegia of childhood: treatment of attacks with chloral hydrate and niaprazine. Eur J Pediatr 1997;156(2):157-8. PMID 9039526
43: Verret S, Steele JC. Alternating hemiplegia in childhood: a report of eight patients with complicated migraine beginning in infancy. Pediatrics 1971;47:675-80. PMID 5089756
44: Vezyroglou A, Akilapa R, Barwick K, et al. The phenotypic continuum of ATP1A3-related disorders. Neurology 2022;99(14):e1511-6. PMID 36192182
45: Viollet L, Glusman G, Murphy KJ, et al. Alternating hemiplegia of childhood: retrospective genetic study and genotype-phenotype correlations in 187 subjects from the US AHCF Registry. PLoS One 2015;10(5):e0127045. PMID 25996915
46: Wang D, Pascual JM, De Vivo D. Glucose transporter type 1 deficiency syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle: University of Washington, 2018.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Nina F. Schor MD PhD

Dr. Schor of the National Institutes of Health has no relevant financial relationships to disclose.
See Profile

Editor

Stephen D Silberstein MD

Dr. Silberstein, Director of the Jefferson Headache Center at Thomas Jefferson University has no relevant financial relationships to disclose.
See Profile

Former Authors

Robert A Davidoff MD (original author) and Marcy E Yonker MD

Patient Profile

Age range of presentation: 1 month to 5 years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Other specified hemiplegia: 342.8
ICD-10: Hemiplegia: G81
OMIM: Alternating hemiplegia of childhood: #104290

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Alternating hemiplegia of childhood

Differential Diagnosis

partial epilepsy
idiopathic torsion dystonia
dopa-responsive dystonia
paroxysmal dystonic choreoathetosis
paroxysmal kinesigenic choreoathetosis
- benign dystonia of infancy
- glutaric aciduria
- GM1 and GM2 gangliosidoses
- Hartnup disease
- pantothenate kinase-associated neurodegeneration
- mitochondrial cytopathy
- congenital and acquired lesions of the basal ganglia
- stroke
- moyamoya disease
- epilepsy
- mitochondrial disease

Also Relevant

Acute cerebellar ataxia in children
Acute hemiplegia in childhood
Childhood migraine
Hemiplegic migraine
Migraine
- Sensorineural hearing loss

Alternating hemiplegia of childhood …

Alternating hemiplegia of childhood

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Acute cerebellar ataxia in children

Late-life migrainous accompaniments

Zika virus: neurologic complications

Headache associated with intracranial neoplasms

Cerebral edema in childhood

CNS germinoma

Vein of Galen malformations

Medication overuse headache

Alternating hemiplegia of childhood

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Acute cerebellar ataxia in children

Late-life migrainous accompaniments

Zika virus: neurologic complications

Headache associated with intracranial neoplasms

Cerebral edema in childhood

CNS germinoma

Vein of Galen malformations

Medication overuse headache

This is an article preview.
Start a Free Account
to access the full version.